Recent in vivo studies show that preserving DNA sequences while altering methylation patterns can be safe and efficacious, encouraging clinical aspirations.
These are the 15 companies that emerged from the best of the best, and we’re proud to call them the industry’s fiercest biotechs for 2023. (Fierce Biotech)
We’ve selected 30 firms that have collectively raised nearly $8 billion. A fair share of these companies are focused on AI techniques to accelerate drug discovery while others have homed in on niche areas like gene therapies, RNA modulation and epigenetic therapies.
Academic spinouts are companies that are typically formed from research taking place at academic institutions and are sometimes launched and owned by the university. A means to turn research into products of commercial value, the biotech industry has witnessed quite a few spinouts develop from research projects over the years.
Have you ever wondered why identical twins can develop different diseases? Take, for example, the hypothetical twins Bob and Jim. Bob eats a diet of sugary, low-fiber food and doesn’t get much exercise. Jim, on the other hand, runs every morning after eating a bowl of oatmeal and drinks red wine in moderation.
The San Francisco-based company has taken a step forward with proof of concept for its ‘switch on or switch off’ approach to gene regulation via non-cutting CRISPR molecules.
To overcome the obstacles for CRISPR-Cas9 gene editing, the startup Epic Bio was launched in July 2022 with an impressive Series A round worth $55 million.
Epic Bio, founded by Stanford bioengineer Stanley Qi, builds pipeline with tiniest Cas protein, epigenetic modulators, a platform that combines them, and proceeds from $55M Series A.
The startup is funded by Horizons Ventures and led by Amber Salzman, who has headed multiple genetic medicine companies, most recently Adverum Biotechnologies.
Controlling the epigenetics of a patient, figuring out what genes are expressed and understanding their level of expression, is at the center of Epic Bio, a new company founded by Stanley Qi.
Epic Bio is controlling target gene expression using single vectors that combine its highly compact Cas protein with guide RNAs and epigenetic modulators.
By not cutting out the bad part of a gene before replacing it with a correct DNA sequence — the essence of the CRISPR editing technology — the South San Francisco company believes its platform can reduce potential errors and side effects to fix a range of genetic diseases.
A former doctoral candidate in CRISPR pioneer Jennifer Doudna’s lab founded a new biotech seeking to wade into “epigenetics-level gene editing,” and has now secured enough capital to do just that.
"🔬 Epic Bio is seeking highly motivated Research Associates, Senior Research Associates and Scientists to expand our efforts in developing transformative therapies for patients. 🔬 https://epic-bio.com/careers/
#Epigenetics #Jobs #ResearchOpportunity #JoinOurTeam #GeneRegulation "
